Program
tezepelumab
Also written as “Tezepelumab”, “Experimental: Tezepelumab” and “MEDI9929”.
Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Dermatitis, Atopic · Nasal Polyps · Rhinosinusitis, led by 3 companies.
Drug pageTezepelumab: every studyAll 48 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 288 open or running | phase 4since Mar 17, 2022 | Jul 30, 2013 | Jan 13, 2027phase 3 · NCT06706817 |
| Amgenits history only | 50 open or running | phase 2since Jan 10, 2019 | Sep 18, 2008 | none ahead |
| Qilu Pharmaceuticalits history only | 11 open or running | phase 3since Dec 11, 2025 | Dec 11, 2025 | Dec 2028phase 3 · NCT07302516 |
Also a collaborator on its studies: Fortrea and Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 19 earlier studies, Sep 18, 2008 to Dec 2, 2020.
- Jun 9, 2015Named tezepelumabINNProposed as its International Nonproprietary Name in WHO's List 113 · before, MEDI9929
- Feb 18, 2021Phase 3 study in Nasal PolypsAstraZeneca · NCT04851964 · 416 enrolled · United States, Canada, China and more
- Apr 5, 2021Phase 2 study in Chronic UrticariaAmgen · NCT04833855 · 183 enrolled · United States, Canada, France and more
- Aug 23, 2021Phase 3 study in Moderate to Severe AsthmaAstraZeneca · NCT05062759 · 70 enrolled · United States
- Jan 27, 2022Phase 3 study in AsthmaAstraZeneca · NCT05274815 · 305 enrolled · United States, Argentina, Belgium and more
- Mar 17, 2022Phase 4 study in AsthmaAstraZeneca · NCT05329194 · 286 enrolled · United States
- May 26, 2022Phase 3 study in AsthmaAstraZeneca · NCT05398263 · 125 enrolled · United States, Brazil, Canada and more
- Oct 13, 2022Phase 3 study in Eosinophilic EsophagitisAstraZeneca · NCT05583227 · 368 enrolled · United States, Australia, Austria and more
- Jul 20, 2023Phase 3 study in AsthmaAstraZeneca · NCT06023589 · 231 planned · United States, Argentina, Brazil and more
- Jun 10, 2024Phase 3 study in AsthmaAstraZeneca · NCT06473779 · 310 enrolled · United States, Argentina, Belgium and more
- Nov 7, 2024Phase 3 study in RhinosinusitisAstraZeneca · NCT06706817 · 181 enrolled · United States, Bulgaria, Canada and more
- Mar 3, 20252 phase 3 studies in Pulmonary Disease, Chronic ObstructiveAstraZeneca · NCT06883305, NCT06878261
- Nov 25, 2025Phase 3 study in AsthmaAstraZeneca · NCT07363642 · 400 planned · China
- Dec 11, 2025Qilu Pharmaceutical’s first study: phase 3 study in AsthmaNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT07302516 · 636 planned
- Mar 24, 2026Phase 3 study in Chronic Rhinosinusitis With Nasal PolypsAstraZeneca · NCT07520162 · 230 planned · China
Ahead
- Jan 13, 2027Primary completion: phase 3 study in RhinosinusitisAstraZeneca · NCT06706817
- Jun 25, 2027Primary completion: phase 3 study in AsthmaAstraZeneca · NCT06473779
- Feb 7, 2028Primary completion: phase 3 study in AsthmaAstraZeneca · NCT07363642
- Mar 1, 2028Primary completion: phase 3 study in Chronic Rhinosinusitis With Nasal PolypsAstraZeneca · NCT07520162
TargetBeta
“Thymic stromal lymphopoietin inhibitor; Thymic stromal lymphopoietin inhibitor”ChEMBL 37, by rule
Other programs on TSLP
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tilrekimig | Pfizer | phase 3 | 11 |
| lunsekimig | Sanofi | phase 3 | 10 |
| felcorekibart | GlaxoSmithKline | phase 3 | 9 |
| SHR-1905 | Jiangsu HengRui Medicine | phase 3 | 7 |
| TQC2731 | Sino Biopharmaceutical | phase 3 | 7 |
| WIN378rule | windward-bio | phase 2 | 2 |
| CDX-622rule | Celldex Therapeutics | phase 1 | 2 |
| HXN-1013rule | Helixon Biotechnology (Suzhou) | phase 1 | 1 |
| HY6725rule | Newsoara Biopharma | phase 1 | 1 |
Studies
All 34 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07520162Chronic Rhinosinusitis With Nasal Polyps · China | 3 | Recruiting | AstraZeneca | Mar 1, 2028 | 230 |
| NCT07302516Asthma | 3 | Not yet recruiting | Qilu Pharmaceutical | Dec 2028 | 636 |
| NCT07363642Asthma · China | 3 | Recruiting | AstraZeneca | Feb 7, 2028 | 400 |
| NCT06883305Pulmonary Disease, Chronic Obstructive · United States, Brazil, Canada and more | 3 | Recruiting | AstraZeneca | Mar 13, 2029 | 990 |
| NCT06878261Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more | 3 | Recruiting | AstraZeneca | Mar 13, 2029 | 990 |
| NCT06706817Rhinosinusitis · United States, Bulgaria, Canada and more | 3 | Active, not recruiting | AstraZeneca | Jan 13, 2027 | 181 |
| NCT06473779Asthma · United States, Argentina, Belgium and more | 3 | Active, not recruiting | AstraZeneca | Jun 25, 2027 | 310 |
| NCT06023589Asthma · United States, Argentina, Brazil and more | 3 | Recruiting | AstraZeneca | May 31, 2028 | 231 |
| NCT05583227Eosinophilic Esophagitis · United States, Australia, Austria and more | 3 | Active, not recruiting | AstraZeneca | Jul 14, 2026 | 368 |
| NCT05398263Asthma · United States, Brazil, Canada and more | 3 | Terminated | AstraZeneca | Mar 24, 2025 | 125 |
| NCT05329194Asthma · United States | 4 | Completed | AstraZeneca | Oct 1, 2025 | 286 |
| NCT05274815Asthma · United States, Argentina, Belgium and more | 3 | Completed | AstraZeneca | Sep 9, 2024 | 305 |
| NCT05062759Moderate to Severe Asthma · United States | 3 | Completed | AstraZeneca | Mar 21, 2022 | 70 |
| NCT04833855Chronic Urticaria · United States, Canada, France and more | 2 | Completed | Amgen | Dec 20, 2022 | 183 |
| NCT04851964Nasal Polyps · United States, Canada, China and more | 3 | Completed | AstraZeneca | Sep 23, 2024 | 416 |
| NCT04673630Asthma · Hungary, South Africa, United Kingdom | 1 | Completed | AstraZeneca | Sep 27, 2022 | 18 |
| NCT04362410Healthy Subjects · China | 1 | Completed | AstraZeneca | Oct 9, 2020 | 48 |
| NCT04039113Pulmonary Disease, Chronic Obstructive · United States, Canada, Denmark and more | 2 | Completed | AstraZeneca | Nov 10, 2023 | 337 |
| NCT03989544Asthma · Germany | 1 | Completed | AstraZeneca | Dec 30, 2019 | 315 |
| NCT04048343Asthma · Japan | 3 | Completed | AstraZeneca | Mar 18, 2021 | 65 |
| NCT03968978Asthma · United States, Canada, Japan and more | 3 | Completed | AstraZeneca | Jun 5, 2020 | 216 |
| NCT03927157Asthma · China, Philippines, South Korea | 3 | Completed | AstraZeneca | May 24, 2024 | 405 |
| NCT03809663Dermatitis, Atopic · United States, Australia, Canada and more | 2 | Terminated | Amgen | May 12, 2020 | 251 |
| NCT03706079Asthma · United States, Argentina, Australia and more | 3 | Completed | AstraZeneca | Oct 26, 2021 | 951 |
| NCT03688074Asthma · United States, Canada, Denmark and more | 2 | Completed | AstraZeneca | Nov 16, 2020 | 116 |
| NCT03406078Asthma · United States, Argentina, Germany and more | 3 | Completed | AstraZeneca | Sep 25, 2020 | 150 |
| NCT03347279Asthma · United States, Argentina, Australia and more | 3 | Completed | AstraZeneca | Sep 8, 2020 | 1,061 |
| NCT02525094Dermatitis, Atopic · United States, Australia, Canada and more | 2 | Completed | AstraZeneca | May 9, 2016 | 113 |
| NCT02512900Asthma · Poland | 1 | Completed | AstraZeneca | May 17, 2016 | 21 |
| NCT02054130Asthma · United States, Bulgaria, Czechia and more | 2 | Completed | AstraZeneca | Dec 12, 2016 | 584 |
| NCT01913028Healthy · Japan | 1 | Completed | AstraZeneca | Jan 2014 | 64 |
| NCT01405963Asthma · Canada | 1 | Completed | Amgen | Apr 5, 2013 | 31 |
| NCT00972179Healthy Volunteers | 1 | Completed | Amgen | Jan 9, 2011 | 49 |
| NCT00757042Dermatitis, Atopic | 1 | Completed | Amgen | Jan 5, 2011 | 78 |
How it is read
Names in the registry
- “Tezepelumab”, 23 entries
- “Experimental: Tezepelumab”, 4 entries
- “MEDI9929”, 2 entries
- “tezepelumab (Arm1&Arm2)”, 1 entry
- “Tezepelumab Dose 1”, 1 entry
Conditions, from the studies’ own filings
- Asthma, 20 studies
- Pulmonary Disease, Chronic Obstructive, 3 studies
- Dermatitis, Atopic, 3 studies
- Nasal Polyps, 2 studies
- Rhinosinusitis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.